Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
R340645-25mg | 25mg | In stock | $489.90 | |
R340645-50mg | 50mg | In stock | $815.90 | |
R340645-100mg | 100mg | In stock | $1,360.90 | |
R340645-250mg | 250mg | In stock | $3,062.90 |
Synonyms | sparsentan | 254740-64-2 | Sparsentan (RE-021) | RE-021 | retrophin | PS433540 | Sparsentan [USAN] | FILSPARI | PS-433540 | UNII-9242RO5URM | DARA | 9242RO5URM | PS 33540 | CHEMBL539423 | 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(e |
---|---|
Specifications & Purity | 98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Type-1 angiotensin II receptor antagonist |
ALogP | 5 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide |
---|---|
INCHI | InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35) |
InChi Key | WRFHGDPIDHPWIQ-UHFFFAOYSA-N |
Canonical SMILES | CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC |
Isomeric SMILES | CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC |
PubChem CID | 10257882 |
Molecular Weight | 592.75 |
PubChem CID | 10257882 |
---|---|
ChEMBL Ligand | CHEMBL539423 |
CAS Registry No. | 254740-64-2 |
BindingDB Ligand | 50175523 |
GPCRdb Ligand | sparsentan |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
K2223528 | Certificate of Analysis | Jul 22, 2022 | R340645 |
K2223531 | Certificate of Analysis | Jul 22, 2022 | R340645 |
K2223532 | Certificate of Analysis | Jul 22, 2022 | R340645 |
K2223533 | Certificate of Analysis | Jul 22, 2022 | R340645 |
1. Murugesan N, Gu Z, Fadnis L, Tellew JE, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Valentine MT et al.. (2005) Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics.. J Med Chem, 48 (1): (171-9). [PMID:15634011] |
2. Morphy R, Rankovic Z. (2005) Designed multiple ligands. An emerging drug discovery paradigm.. J Med Chem, 48 (21): (6523-43). [PMID:16220969] |
3. D'Agati VD, Kaskel FJ, Falk RJ. (2011) Focal segmental glomerulosclerosis.. N Engl J Med, 365 (25): (2398-411). [PMID:22187987] |
4. Hodson EM, Sinha A, Cooper TE. (2022) Interventions for focal segmental glomerulosclerosis in adults.. Cochrane Database Syst Rev, 2 (2): (CD003233). [PMID:35224732] |